Table 6.
Data at the center level is summarized. The mean number of alive patients at the time of the survey was approximately 700. The percentage of patients fully vaccinated was around 87%. The most common type of vaccine was mRNA based in 50% of centers, followed by viral vector type in 31% of the centers.
| Proportion (n) | [95%_Conf. interval] | |||
|---|---|---|---|---|
| LT patients alive (n) | 698.459 | 504.334 | 892.584 | |
| Timing of vaccination administration | <3 months (%) | 25.116 | 9.809 | 40.423 |
| 3–6 months (%) | 50.869 | 21.674 | 80.063 | |
| 6–12 months (%) | 58.748 | 45.334 | 72.162 | |
| >12 months (%) | 72.682 | 66.977 | 78.388 | |
| Globally vaccinated (%) | 86.570 | 81.550 | 91.590 | |
| Patients vaccinated (n)a | 667.120 | 332.030 | 1,002.210 | |
| Type of vaccine administered (%) | mRNA | 49.646 | 17.523 | 81.770 |
| Viral vector | 30.811 | 1.515 | 60.107 | |
| Viral vector and mRNA | 4.695 | 0.502 | 8.888 | |
| Others | 14.968 | −4.681 | 34.618 | |
a
This estimation is based on the number of alive patients (available in 58.9%, n = 99) and the rate of fully vaccinated patients per center (available in 52.5%, n = 88).